Cell Death Discovery (Mar 2024)

USP22 regulates APL differentiation via PML-RARα stabilization and IFN repression

  • Lisa Kowald,
  • Jens Roedig,
  • Rebekka Karlowitz,
  • Kristina Wagner,
  • Sonja Smith,
  • Thomas Juretschke,
  • Petra Beli,
  • Stefan Müller,
  • Sjoerd J. L. van Wijk

DOI
https://doi.org/10.1038/s41420-024-01894-8
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Ubiquitin-specific peptidase 22 (USP22) is a deubiquitinating enzyme (DUB) that underlies tumorigenicity, proliferation, cell death and differentiation through deubiquitination of histone and non-histone targets. Ubiquitination determines stability, localization and functions of cell fate proteins and controls cell-protective signaling pathways to surveil cell cycle progression. In a variety of carcinomas, lymphomas and leukemias, ubiquitination regulates the tumor-suppressive functions of the promyelocytic leukemia protein (PML), but PML-specific DUBs, DUB-controlled PML ubiquitin sites and the functional consequences of PML (de)ubiquitination remain unclear. Here, we identify USP22 as regulator of PML and the oncogenic acute promyelocytic leukemia (APL) fusion PML-RARα protein stability and identify a destabilizing role of PML residue K394. Additionally, loss of USP22 upregulates interferon (IFN) and IFN-stimulated gene (ISG) expression in APL and induces PML-RARα stabilization and a potentiation of the cell-autonomous sensitivity towards all-trans retinoic acid (ATRA)-mediated differentiation. Our findings imply USP22-dependent surveillance of PML-RARα stability and IFN signaling as important regulator of APL pathogenesis, with implications for viral mimicry, differentiation and cell fate regulation in other leukemia subtypes.